C07K16/467 - CPC Classification Index

ClassID:

97235 ⎘

C07K16/467 - CPC Classification

Classification description:

Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies; Hybrid immunoglobulins; Igs containing Ig-regions, -domains or -residues form different species Igs with modifications in the FR-residues only

Recent Application in this class:

20220185881

2022-06-16

ANTI-CLAUDIN 18.2 ANTIBODY AND APPLICATION THEREOF

20210107997

2021-04-15

Antibody with non-natural amino acid introduced therein

20190276525

2019-09-12

ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF PREPARING AND USING THE SAME

20190161540

2019-05-30

ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF PREPARING AND USING THE SAME

20190127488

2019-05-02

Antibody with non-natural amino acid introduced therein

20170313786

2017-11-02

Dual Variable Domain Immunoglobulin and Uses Thereof

20170145088

2017-05-25

HUMANIZED ANTIBODIES

20150057436

2015-02-26

Humanized antibodies

20150038370

2015-02-05

Methods for screening and engineering antibodies

#10

20150017154

2015-01-15

Caninized anti-nerve growth factor antibodies

#11

20140213768

2014-07-31

Dual Variable Domain Immunoglobulin and Uses Thereof

#12

20140147439

2014-05-29

Anti-nerve growth factor antibodies and methods of preparing and using the same

#13

20130004416

2013-01-03

Dual Variable Domain Immunoglobulin and Uses Thereof

#14

20120329069

2012-12-27

METHODS FOR ANTIBODY ENGINEERING

#15

20120003671

2012-01-05

Methods for antibody engineering

#16

20110319597

2011-12-29

VARIANT DOMAIN ANTIBODIES

#17

20110165621

2011-07-07

Humanized antibodies

#18

20100210831

2010-08-19

Immunocytokine sequences and uses thereof

#19

20100047239

2010-02-25

Dual variable domain immunoglobulin and uses thereof

#20

20090252726

2009-10-08

Anti-tissue factor antibodies and methods of use thereof

#21

20090155824

2009-06-18

Methods for antibody engineering

#22

20090092602

2009-04-09

Use of anti-tissue factor antibodies for treating thromboses

#23

20080260735

2008-10-23

Transfer request (37 CFR 1.821(e)) humanised antibodies to the epidermal growth factor receptor

#24

20080248529

2008-10-09

MODIFIED ANTI-CD52 ANTIBODY

#25

20080227957

2008-09-18

Reducing the immunogenicity of anti-CD20 antibodies by framework patching

#26

20080182975

2008-07-31

Framework patched anti-CD20 antibody

#27

20080075715

2008-03-27

Modified anti-CD52 antibody

#28

20070298035

2007-12-27

REDUCING IMUNOGENICITIES OF IMMUNOGLOBULINS BY FRAMEWORK-PATCHING

#29

20070292416

2007-12-20

De-Immunized Anti-Cd3 Antibody

#30

20070071675

2007-03-29

Dual variable domain immunoglobulin and uses thereof

#31

20070059282

2007-03-15

Immunocytokine sequences and uses thereof

#32

20060240003

2006-10-26

Humanised antibodies to the epidermal growth factor receptor

#33

20060235209

2006-10-19

Use of anti-tissue factor antibodies for treating thromboses

#34

20060153837

2006-07-13

Treating autoimmune diseases with humanized anti-CD401 antibodies

#35

20060147446

2006-07-06

Humanized antibodies to human GP39, compositions, and therapeutic uses thereof

#36

20060099204

2006-05-11

Methods for antibody engineering

#37

20060063209

2006-03-23

Engineered antibody fragment that irreversibly binds an antigen

#38

20060039901

2006-02-23

Antibodies for inhibiting blood coagulation and methods of use thereof

#39

20050239141

2005-10-27

Modified antibody variable domains

#40

20050152898

2005-07-14

Modified anti-CD52 antibody

#41

20050048578

2005-03-03

Methods of screening for monoclonal antibodies with desirable activity

#42

20050033028

2005-02-10

Reducing immunogenicities of immunoglobulins by framework-patching